{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:52:41Z","timestamp":1788306761442,"version":"build-2803163510"},"reference-count":28,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The purpose of this article was to unravel the clinical efficacy of probiotics combined with mesalazine and Yiyi Baitouweng Decoction retention enema in the treatment of mild-to-moderate ulcerative colitis (UC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eighty-six mild-to-moderate UC patients were selected as study subjects and randomized into the control group (treated with mesalazine enteric-coated tablets [Salofalk]) and the observation group (treated with mesalazine enteric-coated tablets, Bifidobacterium Tetravaccine Tablets, and Yiyi Baitouweng Decoction retention enema). The clinical efficacy, colonoscopy score, serum levels of inflammatory factors, and the incidence of adverse reactions were compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The clinical efficacy of patients in the observation group was better in contrast to the control group. After 8 weeks of treatment, the colonoscopy score, and levels of TNF-\u03b1, IFN-\u03b3, CRP, and ESR were lower, while IL-10 levels were higher in patients of both groups than those before treatment; lower colonoscopy score and levels of TNF-\u03b1, IFN-\u03b3, CRP, and ESR and higher IL-10 levels were observed in the observation group versus the control group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Probiotics combined with mesalazine and Yiyi Baitouweng Decoction retention enema have remarkable clinical effects in treating mild-to-moderate UC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/med-2024-1126","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T09:44:10Z","timestamp":1740563050000},"source":"Crossref","is-referenced-by-count":4,"title":["Clinical observation of probiotics combined with mesalazine and Yiyi Baitouweng Decoction retention enema in treating mild-to-moderate ulcerative colitis"],"prefix":"10.1515","volume":"20","author":[{"given":"Yanlong","family":"Li","sequence":"first","affiliation":[{"name":"Diagnosis and Treatment Center for Spleen and Stomach Diseases, Gansu Provincial Hospital of Traditional Chinese Medicine , Lanzhou 730030, Gansu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoyu","family":"Li","sequence":"additional","affiliation":[{"name":"College of Integrated Chinese and Western Medicine, Gansu University of Traditional Chinese Medicine , Lanzhou 730000, Gansu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Gou","sequence":"additional","affiliation":[{"name":"College of Integrated Chinese and Western Medicine, Gansu University of Traditional Chinese Medicine , Lanzhou 730000, Gansu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Tian","sequence":"additional","affiliation":[{"name":"Diagnosis and Treatment Center for Spleen and Stomach Diseases, Gansu Provincial Hospital of Traditional Chinese Medicine , Lanzhou 730030, Gansu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Chang","sequence":"additional","affiliation":[{"name":"Chronic Non communicable Disease Control Institute, Gansu Provincial Center for Disease Control and Prevention , Lanzhou 730000, Gansu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoxu","family":"Qu","sequence":"additional","affiliation":[{"name":"Endocrinology Department of Spleen and Stomach Diseases, Xigu District Traditional Chinese Medicine Hospital , Lanzhou 730060, Gansu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"2025122201305021880_j_med-2024-1126_ref_001","doi-asserted-by":"crossref","unstructured":"Feuerstein JD, Moss AC, Farraye FA. Ulcerative colitis. Mayo Clin Proc. 2019;94(7):1357\u201373. 10.1016\/j.mayocp.2019.01.018.","DOI":"10.1016\/j.mayocp.2019.01.018"},{"key":"2025122201305021880_j_med-2024-1126_ref_002","doi-asserted-by":"crossref","unstructured":"Singh S, Feuerstein JD, Binion DG, Tremaine WJ. AGA technical review on the management of mild-to-moderate ulcerative colitis. Gastroenterology. 2019;156(3):769\u2013808.e29. 10.1053\/j.gastro.2018.12.008.","DOI":"10.1053\/j.gastro.2018.12.008"},{"key":"2025122201305021880_j_med-2024-1126_ref_003","doi-asserted-by":"crossref","unstructured":"Segal JP, LeBlanc JF, Hart AL. Ulcerative colitis: An update. Clin Med (Lond). 2021;21(2):135\u20139. 10.7861\/clinmed.2021-0080.","DOI":"10.7861\/clinmed.2021-0080"},{"key":"2025122201305021880_j_med-2024-1126_ref_004","doi-asserted-by":"crossref","unstructured":"Park SH, Kim YM, Yang SK, Kim SH, Byeon JS, Myung SJ, et al. Clinical features and natural history of ulcerative colitis in Korea. Inflamm Bowel Dis. 2007;13(3):278\u201383. 10.1002\/ibd.20015.","DOI":"10.1002\/ibd.20015"},{"key":"2025122201305021880_j_med-2024-1126_ref_005","doi-asserted-by":"crossref","unstructured":"Kucharzik T, Koletzko S, Kannengiesser K, Dignass A. Ulcerative colitis-diagnostic and therapeutic algorithms. Dtsch Arztebl Int. 2020;117(33\u201334):564\u201374. 10.3238\/arztebl.2020.0564.","DOI":"10.3238\/arztebl.2020.0564"},{"key":"2025122201305021880_j_med-2024-1126_ref_006","doi-asserted-by":"crossref","unstructured":"Munkholm P, Michetti P, Probert CS, Elkjaer M, Marteau P. Best practice in the management of mild-to-moderately active ulcerative colitis and achieving maintenance of remission using mesalazine. Eur J Gastroenterol Hepatol. 2010;22(8):912\u20136. 10.1097\/meg.0b013e32833944bf.","DOI":"10.1097\/MEG.0b013e32833944bf"},{"key":"2025122201305021880_j_med-2024-1126_ref_007","doi-asserted-by":"crossref","unstructured":"Ko CW, Singh S, Feuerstein JD, Falck-Ytter C, Falck-Ytter Y, Cross RK, et al. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. Gastroenterology. 2019;156(3):748\u201364. 10.1053\/j.gastro.2018.12.009.","DOI":"10.1053\/j.gastro.2018.12.009"},{"key":"2025122201305021880_j_med-2024-1126_ref_008","doi-asserted-by":"crossref","unstructured":"Moss AC, Peppercorn MA. The risks and the benefits of mesalazine as a treatment for ulcerative colitis. Expert Opin Drug Saf. 2007;6(2):99\u2013107. 10.1517\/14740338.6.2.99.","DOI":"10.1517\/14740338.6.2.99"},{"key":"2025122201305021880_j_med-2024-1126_ref_009","doi-asserted-by":"crossref","unstructured":"Wang Y, Parker CE, Bhanji T, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;4(4):CD000543. 10.1002\/14651858.CD000543.pub4.","DOI":"10.1002\/14651858.CD000543.pub4"},{"key":"2025122201305021880_j_med-2024-1126_ref_010","doi-asserted-by":"crossref","unstructured":"Wang Y, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;2016(5):CD000544. 10.1002\/14651858.CD000544.pub4.","DOI":"10.1002\/14651858.CD000544.pub4"},{"key":"2025122201305021880_j_med-2024-1126_ref_011","doi-asserted-by":"crossref","unstructured":"Sehgal P, Colombel JF, Aboubakr A, Narula N. Systematic review: Safety of mesalazine in ulcerative colitis. Aliment Pharmacol Ther. 2018;47(12):1597\u2013609. 10.1111\/apt.14688.","DOI":"10.1111\/apt.14688"},{"key":"2025122201305021880_j_med-2024-1126_ref_012","doi-asserted-by":"crossref","unstructured":"Chibbar R, Dieleman LA. Probiotics in the management of ulcerative colitis. J Clin Gastroenterol. 2015;49 Suppl 1:S50\u20135. 10.1097\/MCG.0000000000000368.","DOI":"10.1097\/MCG.0000000000000368"},{"key":"2025122201305021880_j_med-2024-1126_ref_013","doi-asserted-by":"crossref","unstructured":"Palumbo VD, Romeo M, Marino Gammazza A, Carini F, Damiani P, Damiano G, et al. The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016;160(3):372\u20137. 10.5507\/bp.2016.044.","DOI":"10.5507\/bp.2016.044"},{"key":"2025122201305021880_j_med-2024-1126_ref_014","doi-asserted-by":"crossref","unstructured":"Ren PW, Yang WJ, Wang DD, Shan JY, Kang DY, Hong Q, et al. Kangfuxinye enema combined with mesalamine for ulcerative colitis: A systematic review and GRADE approach. Evid Based Complement Alternat Med. 2017;2017:6019530. 10.1155\/2017\/6019530.","DOI":"10.1155\/2017\/6019530"},{"key":"2025122201305021880_j_med-2024-1126_ref_015","doi-asserted-by":"crossref","unstructured":"Zhang J, Lin B, Zhang Y, Hu X, Liu T, Liu EH, et al. Baitouweng decoction alleviates ulcerative colitis by regulating tryptophan metabolism through DOPA decarboxylase promotion. Front Pharmacol. 2024;15:1423307. 10.3389\/fphar.2024.1423307.","DOI":"10.3389\/fphar.2024.1423307"},{"key":"2025122201305021880_j_med-2024-1126_ref_016","doi-asserted-by":"crossref","unstructured":"Wei P, He Q, Liu T, Zhang J, Shi K, Zhang J, et al. Baitouweng decoction alleviates dextran sulfate sodium-induced ulcerative colitis by suppressing leucine-related mTORC1 signaling and reducing oxidative stress. J Ethnopharmacol. 2023;304:116095. 10.1016\/j.jep.2022.116095.","DOI":"10.1016\/j.jep.2022.116095"},{"key":"2025122201305021880_j_med-2024-1126_ref_017","doi-asserted-by":"crossref","unstructured":"Xie Q, Yu W, He Y, Deng G, Yang H, Chen J, et al. Efficacy and safety of BaitouWeng decoction for ulcerative colitis: A meta-analysis of randomized and controlled trials. Medicine (Baltimore). 2024;103(27):e38704. 10.1097\/MD.0000000000038704.","DOI":"10.1097\/MD.0000000000038704"},{"key":"2025122201305021880_j_med-2024-1126_ref_018","doi-asserted-by":"crossref","unstructured":"Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2\u201317. 10.1093\/ecco-jcc\/jjab178.","DOI":"10.1093\/ecco-jcc\/jjab178"},{"key":"2025122201305021880_j_med-2024-1126_ref_019","doi-asserted-by":"crossref","unstructured":"Solitano V, D\u2019Amico F, Fiorino G, Paridaens K, Peyrin-Biroulet L, Danese S. Key strategies to optimize outcomes in mild-to-moderate ulcerative colitis. J Clin Med. 2020;9(9):2905. 10.3390\/jcm9092905.","DOI":"10.3390\/jcm9092905"},{"key":"2025122201305021880_j_med-2024-1126_ref_020","doi-asserted-by":"crossref","unstructured":"Danese S, Roda G, Peyrin-Biroulet L. Evolving therapeutic goals in ulcerative colitis: towards disease clearance. Nat Rev Gastroenterol Hepatol. 2020;17(1):1\u20132. 10.1038\/s41575-019-0211-1.","DOI":"10.1038\/s41575-019-0211-1"},{"key":"2025122201305021880_j_med-2024-1126_ref_021","doi-asserted-by":"crossref","unstructured":"Nguyen NH, Fumery M, Dulai PS, Prokop LJ, Sandborn WJ, Murad MH, et al. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Lancet Gastroenterol Hepatol. 2018;3(11):742\u201353. 10.1016\/S2468-1253(18)30231-0.","DOI":"10.1016\/S2468-1253(18)30231-0"},{"key":"2025122201305021880_j_med-2024-1126_ref_022","doi-asserted-by":"crossref","unstructured":"Akbar A, Arnott I, Kennedy NA, Nolan J, Peake S, Whiteoak SR, et al. Recommendations for the optimal use of mesalazine in the management of patients with mild to moderate ulcerative colitis. Br J Hosp Med (Lond). 2021;82(10):1\u201311. 10.12968\/hmed.2021.0399.","DOI":"10.12968\/hmed.2021.0399"},{"key":"2025122201305021880_j_med-2024-1126_ref_023","doi-asserted-by":"crossref","unstructured":"Li S, Yin Y, Xiao D, Zou Y. Supplemental bifid triple viable capsule treatment improves inflammatory response and T cell frequency in ulcerative colitis patients. BMC Gastroenterol. 2021;21(1):314. 10.1186\/s12876-021-01887-2.","DOI":"10.1186\/s12876-021-01887-2"},{"key":"2025122201305021880_j_med-2024-1126_ref_024","doi-asserted-by":"crossref","unstructured":"Shen ZH, Zhu CX, Quan YS, Yang ZY, Wu S, Luo WW, et al. Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation. World J Gastroenterol. 2018;24(1):5\u201314. 10.3748\/wjg.v24.i1.5.","DOI":"10.3748\/wjg.v24.i1.5"},{"key":"2025122201305021880_j_med-2024-1126_ref_025","unstructured":"Rather IA, Majumder R, Alshammari FH, Park JG, Bajpai VK. Review-Ulcerative colitis and probiotics: An overview. Pak J Pharm Sci. 2016;29(5 Suppl):1877\u201380."},{"key":"2025122201305021880_j_med-2024-1126_ref_026","doi-asserted-by":"crossref","unstructured":"Longevity O. Retracted: Efficacy and safety of bifidobacterium quadruple viable bacteria combined with mesalamine against UC management: A systematic review and meta-analysis. Oxid Med Cell Longev. 2023;2023:9826531. 10.1155\/2023\/9826531.","DOI":"10.1155\/2023\/9826531"},{"key":"2025122201305021880_j_med-2024-1126_ref_027","doi-asserted-by":"crossref","unstructured":"Xuan-Qing C, Xiang-Yu LV, Shi-Jia LIU. Baitouweng decoction alleviates dextran sulfate sodium-induced ulcerative colitis by regulating intestinal microbiota and the IL-6\/STAT3 signaling pathway. J Ethnopharmacol. 2021;265:113357. 10.1016\/j.jep.2020.113357.","DOI":"10.1016\/j.jep.2020.113357"},{"key":"2025122201305021880_j_med-2024-1126_ref_028","doi-asserted-by":"crossref","unstructured":"Zhao ZH, Dong YH, Jiang XQ, Wang J, Qin WL, Liu ZY, et al. Five commonly used traditional Chinese medicine formulas in the treatment of ulcerative colitis: A network meta-analysis. World J Clin Cases. 2024;12(22):5067\u201382. 10.12998\/wjcc.v12.i22.5067.","DOI":"10.12998\/wjcc.v12.i22.5067"}],"container-title":["Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2024-1126\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2024-1126\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T01:38:30Z","timestamp":1766367510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2024-1126\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,20]]},"published-print":{"date-parts":[[2025,1,20]]}},"alternative-id":["10.1515\/med-2024-1126"],"URL":"https:\/\/doi.org\/10.1515\/med-2024-1126","relation":{},"ISSN":["2391-5463"],"issn-type":[{"value":"2391-5463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,1]]},"article-number":"20241126"}}